Daily, Fri 6 Nov: China approves a first-of-its-kind stroke-prevention pill
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
Today's East-West Bio Brief daily covers China's approval of Bayer's asundexian (Sunharbo), the world's first Factor XIa inhibitor for stroke risk reduction; Qyuns Therapeutics licensing a preclinical TL1A/IL-17 antibody to Caldera for US$30M upfront; Hinova licensing its oral VAV1 molecular glue to Evommune for US$30M upfront; and InnoCare's Phase 3 of orelabrutinib in chronic ITP. Plus Cloudbreak's CBT-001 pterygium Phase 3, Proteina's AI biofoundry raise in Korea, ANI's bid for Sweden's Egetis, Tianjin University's non-invasive BCI study, device-maker cost pressure at Mindray and United Imaging, and the market mood.
Full transcript and all sources for this episode
Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil holds no positions in any company mentioned.
Chapters
0:00 Intro and AI-voice disclosure
0:48 Bayer Sunharbo FXIa China approval
2:18 Qyuns–Caldera and Hinova–Evommune
4:16 InnoCare orelabrutinib ITP Phase 3
5:24 Cloudbreak CBT-001 pterygium Ph3
6:17 Proteina AI biofoundry raise
6:50 ANI bid for Egetis
7:21 Tianjin BCI and device costs
8:30 Market mood and one thing to watch
Key sources: Bayer: asundexian / Sunharbo China approval · Qyuns–Caldera HKEX announcement · Evommune–Hinova (Fierce Biotech) · InnoCare orelabrutinib ITP Phase 3 (all sources on the episode page)
Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn
Also listen on: Apple Podcasts · Amazon Music · YouTube
Tell us what you want us to read next, or what we got wrong, in the comments on the weekly LinkedIn newsletter.
Podchaser verification: 6TxpjXen2K5q2qI393LX